Biotech Profile (Nasdaq: AMIX) Is A Low Float Past Champ Topping Our Watchlist

During a time of notable progress in neuro-therapeutic technology

*Sponsored Biotech Profile (Nasdaq: AMIX) Is A Low Float Past Champ Topping Our Watchlist *Get Our Updates Faster—Tap Here To Receive SMS Alerts* November 17th Greetings, Friend! During a time of notable progress in neuro-therapeutic technology, attention could quickly become focused on one company driving innovation in precision nerve-targeted therapies for central and peripheral nervous system conditions. This organization is reshaping the management of chronic pain and cardiovascular challenges through its proprietary methods for neural modulation and symptom control.  Their solutions are advancing benchmarks across multiple indications, with platforms leveraging intelligent feedback and targeted tissue engagement to deliver meaningful clinical results. For those with an interest in groundbreaking medical technology, exploring this company further may reveal impressive potential for real-world health impact. And with a low float under 7Mn and a couple of analysts forecasting potential upside exceeding triple-digits each, this Nasdaq-listed biotech looks like an attractive radar candidate. For those keeping track — this isn’t the first time this profile has stood out. It was previously brought into focus earlier this year and followed by a sharp rise of approximately 77% intraday, moving from $1.37 at the open to a high of $2.43 on June 27th. Take a moment—this is one to consider keeping an eye on: Autonomix Medical, Inc. (AMIX) Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. The Autonomix Mission The mission of Autonomix is to dramatically improve the quality of life for millions by empowering the nerve-targeted treatments of tomorrow. The company is committed to equipping physicians with innovative tools that enable unparalleled precision in diagnosis and treatment. As a result, patients can expect more targeted therapies and a renewed sense of hope. With its groundbreaking technology, Autonomix believes it can enable new procedures that were previously not possible. Precision Approach to Pain Management Autonomix Medical, Inc. is a medical device company developing precision nerve-targeted therapies to transform treatment of peripheral nervous system diseases. The Company’s first-in-class platform technology utilizes a proprietary, catheter-based microchip sensing array that we believe surpasses other sensing technology available today and sets a new standard in neural signal detection. For the first time ever, the sensing technology enables the ability to detect and differentiate neural signals by combining ultra-high sensitivity with data processing performed directly at the point of detection. Once target nerves are identified, Autonomix uses its proprietary radio frequency (RF) ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology. Autonomix is initially developing its precision nerve-targeted technology for the treatment of pain associated with pancreatic cancer. Initial results from the Company’s ongoing first-in-human study have shown clinically meaningful and durable pain reduction in the initial phase of the study. By delivering targeted ablation transvascularly through the vessel wall, Autonomix has demonstrated success in pancreatic cancer pain which opens up the possibility of transformative denervation treatment across a number of disease categories including hypertension, chronic pain, cardiology, pulmonology, and gastroenterology through a single, first-in-class platform technology. Platform Expansion Opp. Across High-Value Indications Once validated, the Autonomix platform can extend to a broad range of conditions driven by overactive and dysfunctional nerves: Visceral and tumor-related pain Hypertension and other cardiovascular conditions Abdominal, joint, and lower back pain Pulmonary and digestive diseases Urinary tract disorders Additional organ-specific dysfunctions involving nerve signaling Wherever the nervous system plays a role, Autonomix has the potential to make an impact. This broad applicability represents a major opp. to improve patient outcomes and generate long-term value for stakeholders. The Full Autonomix Market Opp. Grab Sources Here: AMIX Website. AMIX Presentation. ----- And based on multiple potential catalysts, (Nasdaq: AMIX) circles the top of my watchlist. Take a look... #1. A Low Float Could Create An Environment For Heightened Volatility Potential. Yahoo Finance is reporting AMIX to have a float of approximately 6.48Mn shares. What does that mean? It means that volatility potential could be significant on a daily basis. #2. Two Analyst Targets Point To Massive Triple And Quadruple-Digit Upside Potential For AMIX. Not just one, but two different analysts are suggesting AMIX to be undervalued from current chart levels. First off, Ladenburg Thalmann Co. Inc. analyst, Jeffrey S. Cohen, has tagged AMIX with an $8.20 target. From its close on Friday, that target provides AMIX with a potential upside of over 1,000%! Additionally, Maxim Group analyst, Anthony Vendettii, has given AMIX a $5.00 target. That target gives AMIX a potential upside of 575+% from its closing valuation Friday. #3. Transformative Advances Showcase Autonomix Medical’s Breakthrough In Pain-Reducing Healing. Autonomix Medical, Inc. announced powerful results from its PoC 1 study, showing a sustained 66% pain reduction and complete elimination of o-p-ioid use among responders with severe pancreatic cancer pain. Patients reported lasting improvement in quality of life, including better sleep, stronger energy, and enhanced daily activity levels. The company’s precision nerve-targeted technology demonstrated both immediate and long-term pain relief, underscoring its promise as a non-o=p-ioid alternative. These outcomes strengthen Autonomix’s expansion into new cancer pain indications within its ongoing PoC 2 phase and broader therapeutic platform. #4. Autonomix Patent Powers Precision Cardiac Therapies With Closed-Loop Innovation. Autonomix Medical secured U.S. Patent No. 12,369,852 for systems that sense autonomic and cardiac signals, map targets, and deliver closed-loop neuromodulation, denervation, or ablation to precisely treat cardiac tissues, strengthening its competitive moat in a multi-Bn-dollar market. The patent supports applications across arrhythmias, refractory angina, coronary spasm, heart failure, hypertension, and plaque/inflammation modulation, potentially reducing reliance on systemic beta blockers and their side effects. With 120+ issued and pending patents, Autonomix’s expanding global IP portfolio underpins a multi-indication platform spanning cardiology and other high-burden diseases. #5. A Potential Healthy Reversal Could Be Nearing For AMIX. A technical analysis reveals AMIX has several oversold indicators, suggesting a possible reversal setup may be developing. At 4:00PM EST on Friday, AMIX had a 9-Day and 14-Day Relative Strength Index both below 26% and a 14-Day Raw Stochastic below 9%. These technical levels suggest a profile that may be currently undervalued. ----- We're kicking-off coverage right now on Autonomix Medical, Inc. (Nasdaq: AMIX). As soon as updates appear, we'll get them out to you quickly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 11/16/2025 and ending on 11/17/2025 to publicly disseminate information about (AMIX:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid twenty two thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (AMIX:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/amix-3zwhp/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice